Navigation Links
North Shore-LIJ Cancer Institute doctors' editorial published
Date:3/19/2014

LAKE SUCCESS, NY Two North Shore-LIJ Cancer Institute doctors, world-renowned for their research in chronic lymphocytic leukemia (CLL), weigh in on a German study of a new drug therapy for CLL in the March 20 edition of the New England Journal of Medicine, the North Shore-LIJ Health System announced today.

CLL is one of the most common forms of blood cancers, usually affecting those later in life. In an editorial written by Kanti Rai, MD, chief of CLL Research and Treatment Program for the health system, and Jacqueline Barrientos, MD, a research hematologist on staff at the CLL Program, they point out that an important factor in the study is that most of the nearly 800 subjects are elderly with coexisting other health issues.

Until now, researchers have skipped this population in favor of younger and healthier subjects, say the doctors, who also have academic appointments at Hofstra North Shore-LIJ School of Medicine. However, the average age of CLL patients at diagnosis is 72, and most usually have other health problems.

The study focused on the use of obinutuzumab, an antibody that binds to the protein CD20, in subjects with previously untreated CLL and coexisting conditions. Most cases of CLL start in white blood cells that have CD20 on their surface.

Researchers compared the benefits of obinutuzumab with that of another antibody rituximab, which also attacks CD20. Both drugs were combined with the chemotherapy drug chlorambucil. They found that subjects receiving obinutuzumab-chlorambucil had an average of 26.7 months progression-free of the disorder compared to 16.3 for those given rituximab-chlorambucil. To read more about the study, visit the New England Journal of Medicine online.

Findings of the study will have an important impact on future CLL research, explained Dr. Rai, who is also an investigator at North Shore-LIJ's Feinstein Institute for Medical Research. "The researchers' work will encourage future use of obinutuzumab in combination with other drugs and help shape the clinical landscape of CLL in the next decade."


'/>"/>

Contact: Diane O'Donnell
dodonnell2@nshs.edu
516-465-2615
North Shore-Long Island Jewish (LIJ) Health System
Source:Eurekalert

Related medicine news :

1. New online portal, app provide information on tsunami zones in the Northwest
2. A North American first at the Montreal Heart Institute
3. Symtrex Inc. Signs Up with ImmuneSecurity to Launch LogInspect to the North American Market
4. Northwestern launches comprehensive program for patients with bicuspid aortic valve disease
5. Northwestern Medicine hosts the National Marfan Foundations Annual Conference
6. Northwestern researchers investigate treatment for tumor cells in spinal fluid
7. North Texas Cities to Start West Nile Spraying Thursday
8. Northeasterns Barnett Institute announces formation of leading analytics company, BioAnalytix, LLC
9. Power Slowly Returns to Much of Northeast After Sandy
10. Kessler awarded $2 million federal grant for Northern NJ Traumatic Brain Injury System
11. Heart Health Worst in the South, Best in Northeast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... , ... It's not always common knowledge whether or not a certain sickness ... to whether or not they are contagious, and most people don't know the answer ... took a look into the matter. , They discovered that the main reason ...
(Date:4/28/2017)... ... ... enough sleep affects much more than energy – it also has mental and physical benefits. ... motor reaction time, which can increase the risk of having a car accident. , ... the NSF to help you sleep better and feel better:, , ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Radiology Business ... and officers for 2017-2018. The annual board election process has been in place since ... basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, FRBMA, as ...
(Date:4/28/2017)... Harbor, Md. (PRWEB) , ... April 28, 2017 ... ... Care Association of America (UCAOA) and College of Urgent Care Medicine will host ... 2017 workshops, sessions and speakers will help those in the industry adapt to ...
(Date:4/28/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has published ... He does not. Yisrayl says with so many titles and names for the Creator, ... says with a little Scripture, backed with a lot of research, the truth is undeniable. ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 The Global Effective ... to 2022 report has covered and analysed the potential of ... on market size, shares and growth factors. The report identifies ... and opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company ...
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
(Date:4/19/2017)... 2017  Novartis today announced the publication of ... and Blood Institute (NHLBI) of the National Institutes ... with treatment-naïve severe aplastic anemia (SAA) achieved complete ... at the initiation of and concurrently with standard ... sequential treatment groups, or cohorts. Cohort 3 added ...
Breaking Medicine Technology: